Novartis Will Not Split Biosimilars From Sandoz As Part Of Review

Swiss Firm Focused On Carving Out Its Financials And Identifying Scope

 
• By Dean Rudge
  
Concept For Social Distancing And Self Isolating In Coronavirus Covid 19 Pandemic Crisis
Biosimilars will not be kept separate from Sandoz • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products